Frankfurt
15.05.25 | 08:03
30,140 Euro
+1,96 % +0,580
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 229 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 252 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 153 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 289 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04. | XVIVO Perfusion AB: Annual Report 2024 | 255 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 287 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 230 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 364 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| 26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 386 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
| 14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 261 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen | |
| 24.10.24 | XVIVO Perfusion AB: Interim Report January-September 2024 | 307 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), corresponding... ► Artikel lesen | |
| 10.10.24 | XVIVO Perfusion AB: Conference Call on Interim Report | 251 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / October 10, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September... ► Artikel lesen | |
| 19.09.24 | XVIVO Perfusion AB: XVIVO to Acquire a Unique Communication Platform for the Transplant Process | 843 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transplant... ► Artikel lesen | |
| 06.09.24 | Nomination Committee of XVIVO Perfusion AB | 425 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following members have been appointed to XVIVO Perfusion's nomination committee for the 2025... ► Artikel lesen | |
| 16.08.24 | XVIVO Perfusion AB: Results From European Randomized Controlled Study Using XVIVO's Heart Technology Published in The Lancet | 576 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized controlled clinical trial investigating the use of... ► Artikel lesen | |
| 12.07.24 | XVIVO Perfusion AB: Interim Report January - June 2024 | 407 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / July 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2024 (Apr 1 - Jun 30) • Net sales amounted to SEK 210.3 million (154.6), corresponding... ► Artikel lesen | |
| 25.06.24 | XVIVO Perfusion AB: Conference call on Interim Report | 258 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / June 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report April-June... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 61,20 | -1,13 % | Ihre wichtigsten Termine: Alle Blicke auf: Boeing, Bayer, Carl Zeiss Meditec, Rheinmetall, Sixt & Jenoptik | © Foto: Bayer AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| ECKERT & ZIEGLER | 63,25 | +1,28 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Quartalsergebnis
Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose
13.05.2025 / 07:45... ► Artikel lesen | |
| INTUITIVE SURGICAL | 502,50 | +0,36 % | Intuitive Surgical Promotes President Dave Rosa As CEO | SUNNYVALE (dpa-AFX) - Intuitive Surgical, Inc. (ISRG), a biotechnology company, on Thursday announced the promotion of President Dave Rosa as Chief Executive Officer, effective from July 1.... ► Artikel lesen | |
| RHOEN-KLINIKUM | 12,800 | +0,79 % | Stärkung ethischer Standards in Forschung und Patientenversorgung / RHÖN-KLINIKUM Campus Bad Neustadt gründet Ethik-Kommission | Bad Neustadt a.d. Saale (ots) - Die RHÖN-KLINIKUM AG hat am Campus Bad Neustadt eine Ethik-Kommission begründet. Das neue Gremium übernimmt seit März 2025 eine zentrale Rolle bei der Bewertung und Beratung... ► Artikel lesen | |
| HIMS & HERS HEALTH | 52,24 | -0,31 % | Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month | ||
| BICO GROUP | 3,188 | -0,81 % | Bico Group Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| M1 KLINIKEN | 14,800 | -0,80 % | M1 Kliniken mit kräftigem Ergebnisplus im Geschäftsjahr 2024 | Die M1 Kliniken AG hat im Geschäftsjahr 2024 Wachstum bei Umsatz und Ergebnis erzielt. Der Konzernumsatz erhöhte sich um 7 Prozent auf 339,2 Millionen Euro, nach 316,3 Millionen Euro im Vorjahr. Besonders... ► Artikel lesen | |
| BAXTER | 27,655 | -0,38 % | BD files patent infringement lawsuit against Baxter over infusion pump tech | ||
| LIFEWARD | 1,315 | 0,00 % | Lifeward Ltd. Reports First Quarter 2025 Financial Results | U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved... ► Artikel lesen | |
| JD HEALTH | 4,440 | -0,45 % | CCBI Lifts JD HEALTH's TP to HKD45.4; 1Q25 Rev. & GPM Beat | ||
| COOPER COMPANIES | 72,00 | -1,37 % | CooperCompanies Updates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting its results for the first quarter on Thursday, medical devices company CooperCompanies (COO), updated its fiscal year 2025 financial guidance. For the... ► Artikel lesen | |
| SURGICAL SCIENCE SWEDEN | 13,510 | 0,00 % | Surgical Science Sweden AB: Interim report January - March 2025: Strong growth despite macroeconomic uncertainties | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 250.7 (188.2) million, an increase of 33 percent compared with the corresponding period in the preceding year. SEK 18.3 million was acquired revenue.License... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 3,740 | -3,11 % | COMMUNITY HEALTH SYSTEMS INC - 8-K, Current Report | ||
| ONWARD MEDICAL | 4,280 | +0,94 % | ONWARD Medical NV: ONWARD Medical Convocation of the 2025 Annual General Meeting of Shareholders and Proposed Resolutions | EINDHOVEN, the Netherlands, April 30, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX ONWRY), the medical technology company creating innovative spinal cord stimulation therapies... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 66,30 | -1,19 % | XFRA 6XC: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 30,140 Euro und damit +1,96 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.